AKT1 and neoplasm: AKT directly interferes with the key molecule TBK1 downstream of STING, causing the STING-IRF3 signaling pathway to “malfunction,” thereby inhibiting the immune system’s ability to produce type I interferons and allowing tumor cells to evade immune attacks, ultimately rendering drugs (such as tamoxifen) gradually ineffective (47).